- Gestrinone
-
- $10.00 / 1kg
-
2024-03-08
- CAS:16320-04-0
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000kg
- Gestrinone
-
- $0.00 / 1kg
-
2023-11-27
- CAS:16320-04-0
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
- Gestrinone
-
- $15.00 / 1KG
-
2021-07-02
- CAS:16320-04-0
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | Gestrinone Basic information |
| Product Name: | Gestrinone | | Synonyms: | (8s,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one;13-ETHYL-17ALPHA-HYDROXY-18,19-DINORPREGNA-4,9,11-TRIEN-20-YN-3-ONE;D-GESTRINONE;GESTRINONE;9,11-trien-20-yn-3-one,13-ethyl-17-hydroxy-19-dinorpregna-(17-alpha)-1;ethylnorgestrienone;gestrigone;r-2323 | | CAS: | 16320-04-0 | | MF: | C21H24O2 | | MW: | 308.41 | | EINECS: | 685-143-2 | | Product Categories: | Hormone;Active Pharmaceutical Ingredients;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids | | Mol File: | 16320-04-0.mol |  |
| | Gestrinone Chemical Properties |
| Melting point | 150-152°C | | alpha | D20 +84.6° (c = 0.41 in methanol) | | Boiling point | 388.8°C (rough estimate) | | density | 1.1040 (rough estimate) | | refractive index | 1.4900 (estimate) | | storage temp. | -20°C Freezer | | solubility | DMF:20.0(Max Conc. mg/mL);64.85(Max Conc. mM)
DMSO:35.0(Max Conc. mg/mL);113.48(Max Conc. mM)
Ethanol:20.0(Max Conc. mg/mL);64.85(Max Conc. mM)
Ethanol:PBS (pH 7.2) (1:5):0.25(Max Conc. mg/mL);81.06(Max Conc. mM)
Water:1.0(Max Conc. mg/mL);3.24(Max Conc. mM) | | form | A crystalline solid | | pka | 12.76±0.40(Predicted) | | Merck | 14,4415 | | Stability: | Hygroscopic | | InChI | InChI=1S/C21H24O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,9,11,13,18-19,23H,3,5-8,10,12H2,1H3/t18-,19+,20+,21+/m1/s1 | | InChIKey | BJJXHLWLUDYTGC-ANULTFPQSA-N | | SMILES | C1C2C(CC[C@]3([H])C=2C=C[C@@]2(CC)[C@@]3([H])CC[C@]2(C#C)O)=CC(=O)C1 | | CAS DataBase Reference | 16320-04-0(CAS DataBase Reference) |
| RTECS | JF7964000 | | Toxicity | mouse,LDLo,intraperitoneal,1gm/kg (1000mg/kg),BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLDBEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)GASTROINTESTINAL: OTHER CHANGES,Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 16, Pg. 701, 1988. |
| Provider | Language |
|
(8S,13S,14S,17R)-13-Ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
| English |
| | Gestrinone Usage And Synthesis |
| Description | Gestrinone is a synthetic steroid with antiprogesterone and antiestrogenic activities.
It is reported to be useful in the treatment of endometriosis and uterine leiom yomas. | | Chemical Properties | Light Yellow Solid | | Originator | Roussel UCLAF (France) | | Uses | Steroidal antiestrogen, antiprogestogen, analog of Norgestrienone. Antigonadotropin.
Controlled substance. | | Definition | ChEBI: Gestrinone is an oxo steroid. | | Brand name | DIMETROSE | | Side effects | Gestrinone, like danazol, inhibits the synthesis of estrogens and progestogens and has been used mainly to prepare patients with an endometrial disorder for hysterectomy. Its most common adverse effects are nausea, headache, mood changes, rash, hot flushes, weight gain, and discomfort in the joints and muscles. In some cases, there is evidence of masculinization. | | Mode of action | The primary action of gestrinone is on the hypothalamic-pituitary axis, where it inhibits gonadotrophin release with a weak inhibitory effect on its synthesis. It also possesses anti-estrogen activity. The mode of action of gestrinone used for EC is probably inhibition of implantation by acting on the endometrium rather than inhibiting ovulation[1].
| | References |
[1] Xuefeng Gao, Guian Chen, Erruo Wu . “Mechanism of emergency contraception with gestrinone: a preliminary investigation.” Contraception 76 3 (2007): Pages 221-227.
|
| | Gestrinone Preparation Products And Raw materials |
|